Skip to main content
SpringerLink
Log in

Prophylaxe und Therapie von Komplikationen der systemischen Tumortherapie

  • Living reference work entry
  • First Online:
Uroonkologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 139 Accesses

Zusammenfassung

Die Toxizität ist neben dem Ansprechen des Tumors und dem Überleben des Patienten das wichtigste Kriterium zur Beurteilung einer Therapie. Daher bedarf es einer exakten Dokumentation von Nebenwirkungen der jeweiligen Therapie. Therapiebedingte Nebenwirkungen und Folgezustände können nur dann als solche erkannt werden, wenn die Ausgangssituation bekannt ist, d. h. dass alle relevanten Parameter bereits vor Beginn der Therapie überprüft und dokumentiert werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • Aapro MS, Molassiotis A, Oliver I (2005) Anticipatory nausea and vomiting. Support Care Cancer 13:117

    Article  Google Scholar 

  • Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. Eur J Cancer 47:8

    Article  CAS  Google Scholar 

  • Auerbach M, Silberstein PT, Webb RT et al (2010) Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 85:655

    Article  CAS  Google Scholar 

  • Bhojani N, Jeldres C, Patard JJ et al (2008) Toxicities associated with the administration of sorafenib, sunitinib and temserolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53:917

    Article  CAS  Google Scholar 

  • Billingham ME, Mason GW, Bristow MR et al (1978) Anthracycline cardiomyopathy monitored by morphological changes. Cancer Treat Pep 62:865

    CAS  Google Scholar 

  • Bracarda S, Ruggeri EM, Monti M et al (2012) Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. Crit Rev Oncol/Hematol 82:378

    Article  Google Scholar 

  • Bracarda S, Sisani M, Marrocolo F et al (2014) GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer. Crit Rec Oncol/Hematol 89:386

    Article  Google Scholar 

  • Brahmer JR, Lachetti C, Schneider BJ et al (2017) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. https://doi.org/10.1200/JCO2017.77.6385

  • Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Hassison D (1978) Early anthracycline cardiotoxicity. Am J Med 65:823

    Article  CAS  Google Scholar 

  • Bronner A, Hood A (1983) Cutaneous complications of chemotherapeutic agents. J Am Acad Dermatol 9:646

    Article  Google Scholar 

  • Brydoy M, Fossa SD, Klepp O et al (2012) Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer. Br J Cancer 107:1833

    Article  CAS  Google Scholar 

  • Bucaneve G, Micozzi A, Menichetti F et al (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977

    Article  CAS  Google Scholar 

  • Carmichael DJS (1992) Handling of drugs in kidney disease. In: Cameron S, Davison AM, Grünfeld JP, Kerr D, Ritz E (Hrsg) Oxford textbook of clinical nephrology. Univ Press Oxford, Oxford, S 175

    Google Scholar 

  • Chao C, Page JH, Yang SJ et al (2014) History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann Oncol 25:1821

    Article  CAS  Google Scholar 

  • Choueiri TK, Escudier B, Powles T et al (2016) Cabozantinib versus everolimus in advanced renal carcinoma (METEOR): final results from a randomized, open-label. Phase 3 trial. Lancet Oncol 17:917

    Article  CAS  Google Scholar 

  • Clark OA, Lyman GH, Castro AA et al (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23:4198

    Article  CAS  Google Scholar 

  • Cooper JAD Jr, White DA, Matthay RA (1986) Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis 133:321–340

    Google Scholar 

  • Corsello SM et al (2013) Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 98:1361

    Article  CAS  Google Scholar 

  • Cramer P, Bresalier RS (2017) Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Curr Gastroenterol Rep 19:3

    Article  Google Scholar 

  • Crawford J, Armitage J, Balducci L et al (2013) Myeloid growth factors. J Natl Compr Cancer Netw 11:1266

    Article  CAS  Google Scholar 

  • Cullen M, Steven N, Billingham L et al (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353:988

    Article  CAS  Google Scholar 

  • Di Lorenzo G, Porta C, Bellmunt J et al (2011) Toxicities of targeted therapies and their management in kidney cancer. Eur Urol 59:526

    Article  Google Scholar 

  • DKFZ (2016) Allgemeine Terminologie und Merkmale unerwünschter Ereignisse. Deutsches Krebsforschungszentrum, Heidelberg. https://www.tumorzentren.de/tl_files/dokumente/CTCAE_4.03_deutsch_Juni_2016_02_final.pdf. Zugegriffen am 20.02.2019

  • Du XX, Williams DA (1994) Interleukin 11: a multifunctional growth factor derived from the hematopoitic microenvironment. Blood 83:2023

    CAS  PubMed  Google Scholar 

  • EMA: SPC-Axitinib (2012) Summary of product characteristic for Axitinib. EMA Axitinib (label). http://www.ema.europa.eu/doce/en_GB/document_library/EPAR_-_Public_assessment_report/human/002406/WC500132190.pdf

  • EMA: SPC-Bevacizumab (2012) Summary of product characteristics for Bevacizumab. EMA Bevacizumab (label). http://www.ema.europa.eu/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf

  • EMA: SPC-Pazopanib (2012) Summary of product characeristics for Pazopanib. EMA Pazopanib (label). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/00141/WC500094272.pdf

  • EMA: SPC-Sunitinib (2012) Summary of product characteristic for Sunitinib. EMA Sunitinib (label). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000687/WC500057737.pdf

  • EMA:SPC-Everolimus (2012) Summary of product characteristics for Everolimus. EMA Everolimus (label). http://www.ema.europa.eu/docs/en_GB/document_libraray/EPAR_-_Product_Information/human/001038/WC500022814.pdf

  • FDA: SPC-Sunitinib (2012) Summary of product characteristic for Sunitinib. FDA Sunitinib (label). http://www.accesdata.fda.gov/drugsatfda_docs/label/2010/021938s010s01 1s014s0151b1.pdf

  • FDA: SPC-Pazopanib (2012) Summary of product characteristics for Pazopanib. FDA Pazopanib (label). http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022465s-010S-0121b1.pdf

  • Fossa SD, Ous S, Abyholm T, Norman N, Loeb M (1985) Post-treatment fertility in patients with testicular cancer. II. Influence of cis-platin-based combination chemotherapy and of retroperitoneal surgery on hormone and sperm cell production. Br J Urol 57:210

    Article  CAS  Google Scholar 

  • Fossa SD, Heilo A, Botinger O (1990) Unexpected high serum levels in cystectomiced bladder cancer patients with an ileals conduit treated intermediate doses of the drug. J Urol 143:498

    Article  CAS  Google Scholar 

  • Fung C, Fossa SD, Milano MT et al (2013) Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol 31:3807

    Article  Google Scholar 

  • Grunberg SM, Warr D, Gralla RJ et al (2011) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – state of the art. Support Care Cancer 19(Suppl 1):543

    Google Scholar 

  • Haanen JBAG, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(Suppl 4):119

    Article  Google Scholar 

  • Herbst C, Naumann F, Kruse EB et al (2009) Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. Cochrane Database Syst Rev 2009:CD007107

    Google Scholar 

  • Hershman D, Neugut A, Jacobson JS et al (2007) Acute myeloid leukemia or myelodystplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 99:196

    Article  CAS  Google Scholar 

  • Honecker F, Claßen J, Preiß J, Dornoff W (Hrsg) (2018) Taschenbuch Onkologie: Interdisziplinäre Empfehlungen zur Therapie 2018/19. Zuckschwerdt, München

    Google Scholar 

  • Howard R, Gilbert E, Lynch CF et al (2008) Risk of leukemia among survivors of testicular cancer: a population-based study of 42,722 patients. Ann Epidemiol 18:416

    Article  Google Scholar 

  • Jaehde U, Kloft C (2006) Zytostatika maßgeschneidert dosieren, Dosis-Individualisierung in der Krebs-Chemotherapie. Pharm Unserer Zeit 2:150

    Article  Google Scholar 

  • Jain A et al (2017) Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated eneterocolitis. World J Gastroenterol 23:2023

    Article  Google Scholar 

  • Kaplan RS, Wiernik PH (1982) Neurotoxicity of antineoplastic drugs. Semin Oncol 9:103

    CAS  PubMed  Google Scholar 

  • Krege S (2003) Chemotherapy of advanced urological tumors. Onkologie Suppl 4:13

    Google Scholar 

  • Kreisman H, Wolkove N (1992) Pulmonary toxicity of antineiplastic therapy. In: Perry MC (Hrsg) The chemotherapy source book. Williams & Wilkins, Baltimore, S 598

    Google Scholar 

  • Lyman G, Dale D, Wolff DA et al (2010) Acut mywloid leukemia or myelodystplastic syndrome in randomized controlles clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 28:2914

    Article  Google Scholar 

  • Lyman GH, Kuderer NM, Crawford J et al (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117:1917

    Article  Google Scholar 

  • Maughan BL et al (2017) Incidence of immune-related adverse events with program death receptor-1-and program death receptor-1 ligand-directed therapies in genitourinary cancers. Front Oncol 7:56

    Article  Google Scholar 

  • Metcalf D (2018) Hematopoietic cytokines. Blood 111:485

    Article  Google Scholar 

  • Michel SM, Thüroff JW, Wirth M (Hrsg) (2016) Supportivtherapie in der Uroonkologie. In: Die Urologie. Springer, Heidelberg, S 1085

    Google Scholar 

  • Moebus V, Jackisch C, Schneeweiss A et al (2013) Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst 105:1018

    Article  CAS  Google Scholar 

  • Motzer RJ, Hutson TE, Glen H et al (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomized, phase 2, open-label, multicenter trial. Lancet Oncol 16:1473

    Article  CAS  Google Scholar 

  • Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655

    Article  Google Scholar 

  • Nitz U, Gluz O, Zuna I et al (2014) Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. Ann Oncol 25:75

    Article  CAS  Google Scholar 

  • Pedrazzoli P, Farris A, Del Prete S et al (2008) Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 26:1619

    Article  CAS  Google Scholar 

  • Pennock GK, Chow LQ (2015) The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist 20:812

    Article  CAS  Google Scholar 

  • Petersen PM, Hansen SW, Giwercman A, Rorth M, Stakkebaek NE (1994) Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol 5:355

    Article  CAS  Google Scholar 

  • Porta C, Osanto S, Ravaud A et al (2011) Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 47:1287

    Article  CAS  Google Scholar 

  • Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5:95

    Article  CAS  Google Scholar 

  • Richards CJ, Je Y, Schutz FA et al (2011) Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 29:3450

    Article  CAS  Google Scholar 

  • Rosenow EC III, Meyers JL, Swensen SJ, Pisani RJ (1992) Drug-induced pulmonary disease- an update. Chest 102:239

    Article  Google Scholar 

  • S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen (o. J.). www.awmf.de

  • Sauer H (2000) In: Wilmanns W, Huhn D, Wilms K (Hrsg) Internistische Onkologie. Stuttgart/New York, Thieme

    Google Scholar 

  • Saunders DP et al (2013) Systematic review of antimicrobials, mucosal coating agents, anesthetics and analgetics for the management of oral mucositis in cancer patients. Support Care Cancer 21:3191

    Article  Google Scholar 

  • Schmoll HJ, Höffken K, Possinger K (1996) Kompendium Internistische Onkologie, Teil 1, 2. Aufl. Springer, Berlin/Heidelberg/New York/Tokio

    Book  Google Scholar 

  • Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187

    Article  CAS  Google Scholar 

  • Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33:3199

    Article  CAS  Google Scholar 

  • Steensma DP, Sloan JA, Dakhil SR et al (2011) Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 29:97

    Article  CAS  Google Scholar 

  • Thurber WA (1989) Offspring of childhood cancer survivors. J Assoc Pediatr Oncol Nurses 6:17

    Article  CAS  Google Scholar 

  • Tonia T, Mettler A, Robert N et al (2012) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 12:CD003407

    PubMed  Google Scholar 

  • Touw et al (2007) Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy? J Natl Cancer Inst 99:183

    Article  CAS  Google Scholar 

  • Topalian SL et al (2012) Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443

    Article  CAS  Google Scholar 

  • Uraizee I, Cheng S, Moslehi J (2011) Reversible cardiomyopathy associated with sunitinib and sorafenib. New Engl J Med 365:1649

    Article  CAS  Google Scholar 

  • Vahid B, Marik PE (2008) Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 133:528

    Article  CAS  Google Scholar 

  • Vogel WV et al (2012) Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol 30:e7

    Article  Google Scholar 

  • White DA, Camus P, Endo M et al (2010) Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 182:396

    Article  Google Scholar 

  • World Health Organisation (1979) WHO handbook for reporting results of cancer treatment. World Health Organization Offset Publication No. 48, Geneva. Retrieved July 2004

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie, Kinderurologie und urologische Onkologie, Evang. Kliniken Essen Mitte gGmbH, Essen, Deutschland

    Susanne Krege

Authors
  1. Susanne Krege
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanne Krege .

Editor information

Editors and Affiliations

  1. Helios Marien Klinikum Duisburg, Duisburg, Nordrhein-Westfalen, Germany

    Herbert Rübben

  2. Urologische Klinik/Poliklinik, Universitätsklinikum Rostock, Rostock, Mecklenburg-Vorpommern, Germany

    Oliver Hakenberg

  3. Klinik und Poliklinik für Urologie , Universitätsklinikum Jena, Jena, Thüringen, Germany

    Marc-Oliver Grimm

  4. Caritaskrankenhaus St. Josef, Regensburg, Germany

    Maximilian Burger

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Krege, S. (2019). Prophylaxe und Therapie von Komplikationen der systemischen Tumortherapie. In: Rübben, H., Hakenberg, O., Grimm, MO., Burger, M. (eds) Uroonkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54652-9_26-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-54652-9_26-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-54652-9

  • Online ISBN: 978-3-662-54652-9

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Search

Navigation